Lidoplus Pain Relief Cream
FDA Label NDC 70372-723

Full FDA labeling including Indications, Dosage, Usage, and Precautions

Structured Product Label

The following Structured Product Label (SPL) was submitted to the FDA by Centura Pharmaceuticals, Inc for the product Lidoplus Pain Relief (NDC 70372-723). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.

This specific version of the label includes detailed information regarding active ingredients:, indications:, warnings:, keep out of reach of children., do not use, if pregnant or breast feeding,, directions:, other ingredients:, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.

Label Section Quick Index

Active Ingredients:

Lidocaine HCl 4.00%

Indications:

For the temporary relief of pain and itching associated with minor burns, sunburn, minor cuts, scrapes, insect bites and minor skin irritations.

Warnings:

For external use only.

• Avoid contact with eyes. • If condition worsens or symptoms persist for more than seven days, discontinue use and consult physician.

Keep Out Of Reach Of Children.

If swallowed, consult physician.

Do Not Use

in large quantities, particularly over raw surfaces or blistered areas.

If Pregnant Or Breast Feeding,

contact physician prior to use.

Directions:

• Adults and children two-years of age or older: Apply to affected area not more than three to four times daily.

• Children under two-years of age: consult a physician.

Other Ingredients:

Aloe Barbadensis Leaf (Aloe Vera Gel) Juice, Aqua (Deionized Water), Arnica Montana Flower Extract, Boswellia Serrata Extract, C13-14 Isoparaffin, Cetyl Alcohol, Chondroitin Sulfate, Dimethyl Sulfone (MSM), Ethylhexylglycerin, Glucosamine Sulfate, Glyceryl Stearate, Glycerin, Hamamelis Virginiana (Witch Hazel) Extract, Laureth-7, PEG-100 Stearate, Phenoxyethanol, Polyacrylamide, Polysorbate-20, Stearic Acid.

* Please review the disclaimer below.